Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234175 | 0.85 | ATAD2 (0.43) | ATAD2ALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL12658804 | 0.84 | ALDH1A1 (0.45) | ATAD2ALDH1A1KMT2ASMN1; SMN2CYP19A1 | |
| SCHEMBL12658849 | 0.84 | ATAD2 (0.42) | ATAD2ALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL13233745 | 0.83 | PTGDR2 (0.39) | ATAD2ELANEALDH1A1GAANPSR1 | |
| SCHEMBL13233812 | 0.83 | SCN9A (0.39) | ATAD2ELANEALDH1A1KMT2ACYP19A1 | |
| SCHEMBL1368159 | 0.83 | ATAD2 (0.48) | ATAD2ALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5862203 | 0.81 | ATAD2 (0.47) | ATAD2ALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL13234059 | 0.81 | ELANE (0.43) | ATAD2ELANEALDH1A1KMT2APKM | |
| SCHEMBL14609276 | 0.81 | ATAD2 (0.39) | ATAD2ALDH1A1KMT2APKMSMN1; SMN2 | |
| SCHEMBL4501363 | 0.81 | ELANE (0.37) | ATAD2ELANEALDH1A1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919920-B1 | PENTACYCLIC KINASE INHIBITORS | GENENTECH INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| EP-1968950-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007022102-A2 | PENTACYCLIC KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | DCK, DTYMK, TK1 | ATAD2 2249/4885ELANE 4770/4885ALDH1A1 2990/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | ATAD2 2419/4885ELANE 3726/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.